Clinical trials
Schizophrenia trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 7 |
| 2013 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 35 |
| Recruiting | 3 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| The Alfred | 7 |
| Bayside Health | 4 |
| Boehringer Ingelheim | 3 |
| FORUM Pharmaceuticals Inc | 3 |
| Hoffmann-La Roche | 3 |
| Janssen Research & Development, LLC | 3 |
| AstraZeneca | 2 |
| Eli Lilly and Company | 2 |
| Melbourne Health | 2 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Schizophrenia | 46 |
| Psychotic Disorders | 17 |
| Mental Disorders | 5 |
| Cognition Disorders | 3 |
| Bipolar Disorder | 2 |
| Affective Disorders, Psychotic | 1 |
| Autistic Disorder | 1 |
| Depressive Disorder | 1 |
| Disease | 1 |
| Hallucinations | 1 |
Trials
Showing 26 to 46 of 46. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.